Publications dans lesquelles il/elle collabore avec Ana Patiño García (20)

2024

  1. Whole exome sequencing and machine learning germline analysis of individuals presenting with extreme phenotypes of high and low risk of developing tobacco-associated lung adenocarcinoma

    eBioMedicine, Vol. 102

2021

  1. Whole exome sequencing characterization of individuals presenting extreme phenotypes of high and low risk of developing tobacco-induced lung adenocarcinoma

    Translational Lung Cancer Research, Vol. 10, Núm. 3, pp. 1327-1337

2020

  1. Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

    Annals of Oncology, Vol. 31, Núm. 2, pp. 274-282

  2. Performance comparison of two next-generation sequencing panels to detect actionable mutations in cell-free DNA in cancer patients

    Clinical Chemistry and Laboratory Medicine, Vol. 58, Núm. 8, pp. 1341-1348

2019

  1. Distrofias musculares

    Principios de bioquímica clínica y patología molecular (Elsevier España), pp. 405-410

  2. Identification of mutations associated with acquired resistance to sunitinib in renal cell cancer

    International Journal of Cancer, Vol. 145, Núm. 7, pp. 1991-2001

  3. The dynamic use of EGFR mutation analysis in cell-free DNA as a follow-up biomarker during different treatment lines in non-small-cell lung cancer patients

    Disease Markers, Vol. 2019

2018

  1. Genomic characterization of individuals presenting extreme phenotypes of high and low risk to develop tobacco-induced lung cancer

    Cancer Medicine, Vol. 7, Núm. 7, pp. 3474-3483

  2. Liquid Biopsy: From Basic Research to Clinical Practice

    Advances in Clinical Chemistry (Academic Press Inc.), pp. 73-119

2017

  1. Strategies to design clinical studies to identify predictive biomarkers in cancer research

    Cancer Treatment Reviews, Vol. 53, pp. 79-97

2016

  1. Characterization of the antiglioma effect of the oncolytic adenovirus VCN-01

    PLoS ONE, Vol. 11, Núm. 1

  2. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value

    Tumor Biology, Vol. 37, Núm. 10, pp. 13687-13694

2015

  1. Correlation of myelodysplastic syndromes with i(17)(q10) and TP53 and SETBP1 mutations

    British Journal of Haematology

  2. Dietary total antioxidant capacity is associated with leukocyte telomere length in a children and adolescent population

    Clinical Nutrition, Vol. 34, Núm. 4, pp. 694-699

2005

  1. Pediatric meningosarcoma: Clinical evolution and genetic instability

    Pediatric Neurology, Vol. 32, Núm. 5, pp. 352-354

2003

  1. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases

    Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181

2002

  1. Measurement and analysis of the chemotherapy-induced genetic instability in pediatric cancer patients

    Mutagenesis, Vol. 17, Núm. 2, pp. 171-175

2000

  1. Characteristics and value of chromosome aberrations induced by antitumor treatments in pediatric patients with cancer

    Revista de medicina de la Universidad de Navarra, Vol. 44, Núm. 1, pp. 15-24

  2. Nonclonal chromosomal aberrations induced by anti-tumoral regimens in childhood cancer: Relationship with cancer-related genes and fragile sites

    Cancer Genetics and Cytogenetics, Vol. 121, Núm. 1, pp. 78-85

1998

  1. Emergence of secondary acute leukemia in a patient treated for osteosarcoma: Implications of germline TP53 mutations

    Medical and Pediatric Oncology, Vol. 30, Núm. 3, pp. 165-169